Pfizer to present Phase 3 SigVie-002 survival data for sigvotatug vedotin in previously treated NSCLC at ESMO 2026
PFE•Pfizer said it will present late-breaking Phase 3 survival results for sigvotatug vedotin in previously treated non-squamous NSCLC on Oct. 25, 2026, among 45 oncology abstracts planned for ESMO 2026.
1. ESMO presentations
Pfizer flagged 45 oncology abstracts for ESMO 2026 in Madrid, with several readouts scheduled for late October. The Phase 3 survival results for sigvotatug vedotin will be presented on Oct. 25.
2. Other study data
Phase 2 FOURLIGHT-1 data for atirmociclib with fulvestrant in HR+/HER2- metastatic breast cancer are scheduled for Oct. 24. Updated Phase 2 results for tivunatamig with chemotherapy in first-line PD-L1-expressing NSCLC are scheduled for Oct. 26. Pfizer also outlined new analyses supporting PADCEV with pembrolizumab in urothelial cancer.
